

Therapeutics Symposium

From Basic Research to Drugs in Patients

17th November 2016

- 9.00 Registration
9.30-9.45 Introduction **Tony Kouzarides**

Session 1, Chair: Mathew Garnett

- 9.45-10.15 **Bill Sellers (Formerly Novartis)** - *Linking the discovery of cancer vulnerabilities to therapeutic development*
10.15-10.35 **Susan Galbraith (AstraZeneca)** - *AZ Oncology Innovative Medicines - Focus on DNA Damage and Cell Death*
10.35-11.05 **Charles Swanton (Francis Crick Institute)** - *Chromosomal Chaos and Cancer Evolution*

Coffee

Session 2, Chair: Susan Galbraith

- 11.30-12.00 **David Rubinsztein (CIMR)** - *Autophagy and related pathways that protect against neurodegeneration*
12.00-12.20 **Rab Prinjha (GSK)** - *Epigenetic Targets for the Treatment of Human Diseases*
12.20-12.50 **Peter McNaughton (King's College London)** - *Development of selective blockers of HCN2 ion channels as novel analgesic*
12.50-13.10 **Nick Pullen (Pfizer)** - *Building the next innovative therapies in inflammation & fibrosis*

Lunch

Session 3, Chair: Gerard Evan

- 2.30-3.00 **Molly Stevens (Imperial College London)** - *Designing materials to detect disease and heal the body*
3.00-3.20 **Harren Jhoti (Astex)** - *Fragment-Based Drug Discovery: the advantage of thinking small*
3.20-3.40 **Tsuneaki Sakata (Shionogi)** - *R&D Focus -Infectious Diseases*
3.40-4.10 **Allan Bradley (Sanger Institute)** - *Complete humanisation of the mouse immunoglobulin loci for therapeutic antibody discovery*

- 4.10-4.15 Concluding Remarks **Tony Kouzarides**
4:15-6:00 Posters and Drinks